Auinger, D. (2022): Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for secondary peritoneal carcinomatosis: 1st Update. Decision Support Document 74/ Update 2022.

Erdos, J. and Stanak, M. (2016): Magnetic sphincter augmentation device (MSAD) in patients with gastroesophageal reflux disease (GERD). Decision Support Document 101.

Falkner, E. and Wild, C. (2008): Clinical application of Tissue Engineering: An overview of International and Austrian Areas of Research with a critical analysis of selected applications . LBI-HTA Projektbericht 013.

Kisser, A. and Kirisits, A. (2014): Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy of peritoneal carcinomatosis . Decision Support Document 74.

Nachtnebel, A (2015): Ramucirumab in combination with paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction carcinoma. DSD: Horizon Scanning in Oncology 54.

Riegelnegg, M. and Gassner, L. and Grössmann-Waniek, N. (2023): Robot-assisted surgery in thoracic and visceral indications – Update 2023. HTA-Projektbericht 108/ Update 2023.

Rothschedl, E. and Grössmann, N. (2023): Pembrolizumab (Keytruda®) with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction adenocarcinoma. Fact Sheet Nr. 155.

Rothschedl, E. and Grössmann, N. (2023): Pembrolizumab (Keytruda®) with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction (GEJ) adenocarcinoma. Update July/August 2023. Fact Sheet Nr. 145.

Rothschedl, E. and Wolf, S. (2022): Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. Update April 2023. Oncology Fact Sheet Nr. 115.

Rothschedl, E. and Wolf, S. (2022): Pembrolizumab (Keytruda®) as monotherapy for the treatment of microsatellite instability-high (MSI‑H) or mismatch repair deficient (dMMR) tumours in adults with unresectable or metastatic colorectal cancer, advanced or recurrent endometrial carcinoma and unresectable or metastatic gastric, small intestine, or biliary cancer. Update July 2022. Oncology Fact Sheet Nr. 90.

Rothschedl, E. and Wolf, S. (2021): Ripretinib (Qinlock®) for the treatment of patients with advanced gastrointestinal stromal tumour (GIST). Update May 2022. Oncology Fact Sheet Nr. 62.

Rothschedl, E. and Wolf, S. and Grössmann, N. (2021): Avapritinib (Ayvakyt®) for the treatment of gastrointestinal stromal tumours (GIST). Update September 2022. Oncology Fact Sheet Nr. 16.

Schmidt , L. and Lohr, P. and Prenner, A. and Poerio, E. and Ceresola, E. and Andretta, M. and Cavazzana, A. (2019): Robot-assisted surgery in thoracic and visceral indications. HTA-Projektbericht 108.

Schott, G. (2010): Trastuzumab (Herceptin®) in addition to standard chemotherapy as first-line therapy for advanced gastric cancer. DSD: Horizon Scanning in Oncology 12.

Stanak, M. and Hawlik, K. (2017): Electric stimulation therapy in patients with gastroesophageal reflux disease. Decision Support Document 104.

Wolf, S. (2021): Nivolumab (Opdivo®) in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the treatment of patients with HER2 negative advanced or metastatic gastric, gastro oesophageal junction or oesophageal adenocarcinoma. Update February 2022. Oncology Fact Sheet Nr. 63.